Skinny labels, big stakes: SCOTUS lines up the case of the year
The court’s review of a high-profile dispute could offer clarity on a grey area for pharma companies and generic drug makers, but also prompt fresh questions.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
9 February 2026 The Swiss pharma giant moves to protect patents on its billion-dollar cancer therapy following an ANDA filing by a Canadian generics manufacturer.
3 February 2026 Nominations are open for the Life Sciences Patent Network's 2026 awards in Boston, including six new categories and winners selected by leading industry experts.